Abstract：Objective To evaluate the clinical efficacy and safety of aripiprazole in the treatment of childhood tic disorders (TD) by a meta analysis. Methods A systematic search for randomized controlled trials (RCTs) on the efficacy and safety of aripiprazole in the treatment of childhood TD that were published between January 2000 and August 2014 was conducted. A Meta analysis on the selected RCTs was conducted using Review Manager 5.2 software. Results Six RCTs involving 551 TD patients were enrolled. There were no significant differences in the efficacy between aripiprazole and traditional drugs for treatment of TD either by the end of follow-up visit or at 2 weeks, 4 weeks and 8 weeks after treatment. The subgroup analysis results indicated that aripiprazole had the same efficacy for the treatment of TD as traditional drug haloperidol. Aripiprazole had a lower incidence of extrapyramidal reactions than haloperidol (PConclusions The available evidence suggests that aripiprazole has the same curative effect in the treatment of childhood TD compared with the traditional drugs. However, it is difficult to draw a firm conclusion that aripiprazole is a safer drug in the treatment of childhood TD.
FANG Qiong,CHEN Lang,CHEN Qiao-Bing et al. Efficacy and safety of aripiprazole in the treatment of childhood tic disorders: a Meta analysis[J]. CJCP, 2015, 17(7): 715-720.
Ghanizadeh A, Mosallaei S. Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome[J]. Brain Dev, 2009, 31(1): 15-19.
[3]
Rasmussen C, Soleimani M, Carroll A, et al. Neuropsychological functioning in children with Tourette syndrome (TS)[J]. J Can Acad Child Adolesc Psychiatry, 2009, 18(4): 307-315.
[4]
Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome[J]. Neurology, 2003, 60(7): 1130-1135.
[5]
Budman CL, Gayer A, Lesser M, et al. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder[J]. J Clin Psychiatry, 2001, 62(4): 290-294.
[6]
Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder[J]. Am J Psychiatry, 1997, 154(8): 1057-1062.
[7]
Hounie A, De Mathis A, Sampaio AS, et al. Aripiprazole and Tourette syndrome[J]. Rev Bras Psiquiatr, 2004, 26(3): 213.
[8]
Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. Available at:
Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder[J]. J Clin Psychiatry, 2013, 74(8): e772-e780.
[14]
Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial[J]. Child Psychiatry Hum Dev, 2013, 45(5): 596-603.
[15]
Seo WS, Sung HM, Sea HS, et al. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder[J]. J Child Adolesc Psychopharmacol, 2008, 18(2): 197-205.
[16]
Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders[J]. J Clin Psychiatry, 2007, 68(7): 1088-1093.
Gulisano M, Cali PV, Cavanna AE, et al. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome[J]. Neurol Sci, 2011, 32(6): 1213-1217.
[19]
Degrauw RS, Li JZ, Gilbert DL. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome[J]. Pediatr Neurol, 2009, 41(3): 183-186.
[20]
Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with tic disorders[J]. J Child Adolesc Psychopharmacol, 2009, 19(4): 441-447.
[21]
Davies L, Stern JS, Agrawal N, et al. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole[J]. Hum Psychopharmacol, 2006, 21(7): 447-453.
Kirschbaum KM, Hiemke C, Schmitt U. Rotarod impairment: catalepsy-like screening test for antipsychotic side effects[J]. Int J Neurosci, 2009, 119(10): 1509-1522.
[24]
Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study[J]. J Child Adolesc Psychopharmacol, 2009, 19(6): 623-633.
